MYT1

Myelin transcription factor 1 · Q01538 · MYT1 on Sugi Atlas →

4,911 patent compounds predicted against MYT1, 3,819 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dasatinib Anhydrous (SCHEMBL8226)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL1704366)	0.98	2/20
Dasatinib Anhydrous (SCHEMBL1705152)	0.98	2/20
Dasatinib Anhydrous (SCHEMBL3468968)	0.96	2/20
Dasatinib Anhydrous (SCHEMBL1363032)	0.94	2/20
SCHEMBL1704876	0.92	2/20
Dasatinib Anhydrous (SCHEMBL4234680)	0.91	2/20
Dasatinib Anhydrous (SCHEMBL1362204)	0.90	2/20
SCHEMBL3507589	0.88	2/20
SCHEMBL3510181	0.87	2/20
Dasatinib Anhydrous (SCHEMBL1767233)	0.87	2/20
SCHEMBL1705125	0.86	2/20
SCHEMBL4783054	0.85	2/20
SCHEMBL1147156	0.84	2/20
SCHEMBL1147171	0.84	2/20
SCHEMBL1704971	0.83	2/20
SCHEMBL12299260	0.83	2/20
Dasatinib Anhydrous (SCHEMBL4236003)	0.82	2/20
SCHEMBL4552090	0.82	2/20

Clinical trials — most relevant to MYT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone	PHASE4	COMPLETED
Intravenous Immunoglobulin Therapy in Optic Neuritis	PHASE3	COMPLETED
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients	PHASE2/PHASE3	COMPLETED
Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis	PHASE2	COMPLETED
Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)	PHASE2	COMPLETED
Fingolimod in Schizophrenia Patients	PHASE2	COMPLETED
Safety and Efficacy of BMMNC in Multiple Sclerosis (MS)	PHASE1/PHASE2	UNKNOWN
Safety and Tolerability of Quetiapine in Multiple Sclerosis	PHASE1/PHASE2	COMPLETED
The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.	PHASE1	COMPLETED
Natural History of the Leukodystrophies	nan	COMPLETED
MYT1L Syndrome: a Rare Paediatric Genetic Syndrome Responsible for a Neurodevelopmental Disorder	nan	RECRUITING
The Classification and Cause of Leukodystrophies of Unknown Cause	nan	COMPLETED
Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS)	nan	COMPLETED
Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Morquio Disease	nan	COMPLETED
Application of ihMT MRI in Multiple Sclerosis	nan	RECRUITING
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients	nan	COMPLETED
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies	nan	COMPLETED
Collection of Blood Samples for DNA in Motor Neuron Disease	nan	COMPLETED
B3 for NMD: Bench to Bedside and Back	nan	ENROLLING_BY_INVITATION
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others	nan	RECRUITING
The Utilization of Yoga as a Therapeutic Tool to Promote Physical Activity Behavior Change and Improved Postural Control in Individuals With Multiple Sclerosis	nan	WITHDRAWN
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease	nan	WITHDRAWN
Longitudinal Biomarkers With Selected Outcome Measures In CMT	nan	RECRUITING
Evaluation of the Regeneration Capacity of Satellite Cells From the Quadriceps Compared to That of the Diaphragm	nan	COMPLETED
Longitudinal Assessment of Iron Rims in MS Lesions	nan	RECRUITING
Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MYT1 binder may also engage these)

Protein	Name	Similarity
Q8CFC2	—	1.000	Q8CFC2 →
P70047	—	1.000	P70047 →
O60284	—	0.998	O60284 →
P10244	—	0.997	P10244 →
BPTF	Nucleosome-remodeling factor subunit BPTF	0.996	landscape →
O54963	—	0.995	O54963 →
Q66J90	—	0.995	Q66J90 →
Q2PFD7	—	0.995	Q2PFD7 →
Q96JQ2	—	0.995	Q96JQ2 →
Q8C5W0	—	0.995	Q8C5W0 →
Q3T0A6	—	0.995	Q3T0A6 →
Q92539	—	0.995	Q92539 →
Q99PI5	—	0.995	Q99PI5 →
Q5DW34	—	0.995	Q5DW34 →
Q90ZS6	—	0.994	Q90ZS6 →
Q5VZP5	—	0.994	Q5VZP5 →
Q9H8G2	—	0.994	Q9H8G2 →
Q60542	—	0.994	Q60542 →
TET3	Methylcytosine dioxygenase TET3	0.994	landscape →
Q499D0	—	0.994	Q499D0 →
P70475	—	0.994	P70475 →
Q9QX27	—	0.994	Q9QX27 →
Q86TC9	—	0.994	Q86TC9 →
Q9D4V4	—	0.994	Q9D4V4 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.994	landscape →
Q9P1A6	—	0.994	Q9P1A6 →
Q5VZ18	—	0.994	Q5VZ18 →
Q62947	—	0.993	Q62947 →
Q9W1R4	—	0.993	Q9W1R4 →
Q80TY4	—	0.993	Q80TY4 →